Movers and SHAKERS
Wednesday, July 10, 2019
Trovagene Inc. (TROV)
What does Colorectal Cancer Trial Add?
TrovaGene Inc is a US-based life science company which focuses on the development and commercialization of a proprietary molecular genetic detection technology for use in pharmaceutical development, clinical research and medical testing across a variety of clinical disciplines, including oncology and virology.
Ahu Demir, Ph.D., Biotechnology Research Analyst, Noble Capital Markets, Inc.
Refer to full report for price target, fundamental analysis and rating.
- Colorectal cancer is the third active clinical trial assessing Onvansertib.. Trovagene initiated patient enrollment in a Phase 1b/2 clinical trial for the treatment of KRAS-mutated metastatic colorectal cancer (mCRC) on July 9, 2019. In addition to this trial, Trovagene is currently evaluating Onvansertib in a Phase 1b/2 study of acute myeloid leukemia (AML), and in a Phase 2 trial of metastatic castration-resistant prostate cancer (mCRPC).
- Unfulfilled need in colorectal cancer treatment.. Among the three cancer types targeted by Onvansertib, colorectal cancer represents the largest...
*Analyst certification and important disclosures included in full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.